Anirvan Ghosh - 28 Mar 2025 Form 4 Insider Report for Unity Biotechnology, Inc. (UBX)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: UBX
Reported as of: 28 Mar 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 31 Mar 2025, 16:15:03 UTC
Prior SEC filing: 05 Feb 2025
Next SEC filing: 03 Apr 2025
Source filing: View source filing
Reporting owner signature: /s/ Alexander Nguyen, Attorney-in-Fact for Anirvan Ghosh

Key filing fact

Anirvan Ghosh filed Form 4 for Unity Biotechnology, Inc. (UBX) on 31 Mar 2025.

Key facts

This page summarizes Anirvan Ghosh's Form 4 filing for Unity Biotechnology, Inc. (UBX).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 31 Mar 2025, 16:15.

Change

Previous filing in this sequence was filed on 05 Feb 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

UBX transaction

Common Stock, $0.0001 par value

Award

Transaction value: $0
Shares: +175,000
Change %: +233%
Price: $0.000000
Shares after: 250,251
Date: 28 Mar 2025
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

UBX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +286,000
Change %
Price: $0.000000
Shares after: 286,000
Date: 28 Mar 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 286,000
Exercise price: $1.67
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

On January 30, 2024, the Board of Directors granted the Reporting Person 175,000 Restricted Stock Units ("RSUs") that vest in full upon the satisfaction of certain performance criteria, which were met on March 28, 2025.

Footnote F2

Includes RSUs that vest over time measured from the grant date.

Footnote F3

On January 30, 2024, the Board of Directors granted the Reporting Person an option to purchase 286,000 shares of common stock. The underlying shares vest and become exercisable pursuant to the following schedule: one half of the shares subject to the option vest upon the satisfaction of certain performance criteria, which were met on March 28, 2025, and the remaining shares subject to the option vest in 12 successive, equal monthly installments thereafter until fully vested, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date.